Clinical Trial Update: EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan [Phase 3]

View source ↗

Summary

Phase 3 EVEREST trial evaluating tolvaptan, a vasopressin antagonist, for congestive heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Samsca (tolvaptan) (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Congestive Heart Failure | Phase 3 | Status: COMPLETED